Ivosidenib in combination with Azacitidine in a phase III trial improved event-free survival, response, and overall survival compared with placebo and azacitidine-only treatment in mutant-IDH1 AML patients (NCT03173248) [177]. This evidence concerns the gene IDH1 and acute myeloid leukemia.